CEVEC Again Successful in Challenge to Crucell N.V. (CRXL) Patent
1/14/2008 9:56:23 AM
Cologne, Germany, January 14, 2008 / b3c newswire / - CEVEC Pharmaceuticals GmbH, the specialist supplier for human expression technologies, today announced that an opposition to a patent owned by Crucell N.V., Leiden, Netherlands (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX), before the European Patent Office was again successful. This is the second time within a year that the Opposition Division of the European Patent Office (EPO) has restricted a patent on Crucell’s PER.C6 cell line.
comments powered by